WASHINGTON DCA new type of immunotherapy has brought responses in children with acute lymphoblastic leukaemia in relapse who had no other options to prevent the progress of this fatal phase of the disease. At the American Association for Cancer Research annual meeting Dr Daniel W. Lee from the Pediatric Oncology Branch of the National Cancer Institute in Bethesda, Maryland, presented findings from his groups study using chimeric antigen receptor T-cell therapy, which involves removing T cells from the child, stimulating and genetically engineering them before re-infusing them in a primed state to fight the cancer. He discusses his findings and the clinical implication with AudioMedica.com. audiomedica.com